

Ferghana Partners advised Schering AG on Refludan transaction with Pharmion

News Story June 6, 2002

NEW YORK, NEW YORK, June 6, 2002

Schering AG of Berlin, Germany, has completed an exclusive agreement with Pharmion Corp. of Boulder, Colorado, whereby Pharmion will develop and market Refludan™ outside of North America. Schering will continue to develop and market Refludan™ in Canada and the U.S. Refludan™ is currently a treatment for Heparin Induced Thrombocytopenia (HIT) and is approved for use in the U.S., Canada, Europe, and other countries. Schering and Pharmion can collaborate in the further clinical development of Refludan™ for other disease indications. Ferghana Partners, of London and New York, advised Schering on the transaction.

Ferghana Partners is an investment-banking group working exclusively in the life sciences area. It was formed in 1992 to serve as a worldwide strategic transaction advisor to clients in the pharmaceutical, biotech, specialty chemicals, and diagnostic industries from its offices in London and New York. Ferghana Partners advises clients on corporate development, ownership and business portfolio topics, such as corporate partnering, mergers, acquisitions, joint ventures and divestitures, as well as equity placements.